Proceedings of the 2019 Viral Clearance Symposium, Session 4: Viral Clearance Strategy and Process Understanding

References

1. 1.↵
   1. Hepbildikler S.,
   2. Nothelfer F.

   Proceedings of the 2017 Viral Clearance Symposium—. PDA J. Pharm. Sci. Technol. 2018, 72 (5), 453–454. doi: https://doi.org/10.5731/pdajpst.2018.009076

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Willkommen H.

   Session 2/3: Integrated Viral Clearance Strategy and Case Studies. PDA J. Pharm. Sci. Technol. 2015, 69 (1), 183–194. doi: https://doi.org/10.5731/pdajpst.2015.01042

   OpenUrlFREE Full Text
3. 3.↵
   1. Blümel J.,
   2. Tounekti O.

   Session 4: Overall Integrated Viral Clearance and Adventitious Agents Strategy. PDA J. Pharm. Sci. Technol. 2015, 69 (1), 195–205. January DOI: https://doi.org/10.5731/pdajpst.2015.0104

   OpenUrlFREE Full Text
4. 4.↵
   International Conference for Harmonisation, ICH Harmonised Tripartite Guideline Q5A(R1): Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. ICH: Geneva, 1999.
5. 5.↵
   International Conference for Harmonisation, ICH Harmonised Tripartite Guideline Q8(R2) Step 4: Pharmaceutical Development. ICH: Geneva, 2009.
6. 6.↵
   International Conference for Harmonisation, Quality Guideline Q10: Pharmaceutical Quality System (PQS). ICH: Geneva, 2008.
7. 7.↵
   International Conference for Harmonisation, Quality Guideline Q11: Development and Manufacture of Drug Substances. ICH: Geneva, 2012.
8. 8.↵
   European Medicines Agency, Meeting Report: Joint BWP/QWP Workshop with Stakeholders in Relation to Prior Knowledge and Its Use in Regulatory Applications; EMA/CHMP/BWP/187162/2018; EMA: London, 2018.
9. 9.↵
   1. Schwantes A.,
   2. Specht R.,
   3. Chen Q.

   Proceedings of the 2017 Viral Clearance Symposium, Session 4: Submission Strategies. PDA J. Pharm. Sci. Technol. 2018, 72 (5), 498–510.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    ASTM International, ASTM E2888 Standard Practice for Process for Inactivation of Rodent Retrovirus by pH. ASTM: West Conshohocken, PA, 2012.
11. 11.↵
    ASTM International, ASTM E3042 Standard Practice for Process Step to Inactivate Rodent Retrovirus with Triton X-100 Treatment. ASTM: West Conshohocken, PA, 2016,
12. 12.↵
    1. Gefroh E.,
    2. Dehghani H.,
    3. McClure M.,
    4. Connell-Crowley L.,
    5. Vedantham G.

    Use of MMV as a Single Worst-Case Model Virus in Viral Filter Validation Studies. PDA J. Pharm. Sci. Technol. 2014, 68 (3), 297–311.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Lute S.,
    2. Norling L.,
    3. Hanson M.,
    4. Emery R.,
    5. Stinson D.,
    6. Padua K.,
    7. Blank G.,
    8. Chen Q.,
    9. Brorson K.

    Robustness of Virus Removal by Protein A Chromatography is Independent of Media Lifetime. J. Chromatogr. A 2008, 1205 (1–2), 17–25.

    OpenUrlPubMed
14. 14.↵
    1. Blümel J.,
    2. Ma J.

    Proceedings of the 2017 Viral Clearance Symposium, Session 3: Resin Lifetime. PDA J. Pharm. Sci. Technol. 2018, 72 (5), 488–497.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Mattila J.,
    2. Curtis S.,
    3. Webb-Vargas Y.,
    4. Wilson E.,
    5. Galperina O.,
    6. Roush D.,
    7. Tobler S.,
    8. Stanley B.,
    9. Clark M.,
    10. Weaver J.,
    11. Pike J.,
    12. Yu D.,
    13. Li X.,
    14. Flicker A.,
    15. Kindermann J.,
    16. Schuelke N.,
    17. Whitcombe R.,
    18. Bennett L.

    Retrospective Evaluation of Cycled Resin in Viral Clearance Studies—A Multiple Company Collaboration. PDA J. Pharm. Sci. Technol. 2019, 73 (5), 470–486. doi: https://doi.org/10.5731/pdajpst.2018.009605

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Cetlin D.,
    2. Pallansch M.,
    3. Fulton C.,
    4. Vyas E.,
    5. Shah A.,
    6. Sohka T.,
    7. Dhar A.,
    8. Pallansch L.,
    9. Strauss D.

    Use of a Noninfectious Surrogate to Predict Minute Virus of Mice Removal during Nanofiltration. Biotechnol. Prog. 2018, 34 (5), 1213–1220. doi: 10.1002/btpr.2694)

    OpenUrl
17. 17.↵
    1. Orchard J. D.,
    2. Cetlin D.,
    3. Pallansch M.,
    4. Barlow R.,
    5. Borman J.,
    6. Dhar A.,
    7. Pallansch L.,
    8. Dickson M.

    Using a Noninfectious MVM Surrogate for Assessing Viral Clearance during Downstream Process Development. Biotechnol. Prog. 2020, 36 (1), e2921. doi: 10.1002/btpr.2921

    OpenUrl
18. 18.↵
    1. Miesegaes G.,
    2. Bailey M.,
    3. Willkommen H.,
    4. Chen Q.,
    5. Roush D.,
    6. Blümel J.,
    7. Brorson K.

    Proceedings of the 2009 Viral Clearance Symposium. Dev. Biol. (Basel, Switz.) 2010, 133, 3–101.

    OpenUrl
19. 19.↵
    1. Roush D.,
    2. Kreil T. R.

    Proceedings of the 2017 Viral Clearance Symposium, Session 2.2: DSP Unit Operations–Purification Unit Operations. PDA J. Pharm. Sci. Technol. 2018, 72 (5), 479–487.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    1. Blümel J.,
    2. Brorson K.

    Session 2: Company-Specific Data on Cycled Resin Testing. PDA J. Pharm. Sci. Technol. 2016, 70 (5), 428–442.

    OpenUrlFREE Full Text
21. 21.↵
    1. Roush D.

    Viral Clearance Using Traditional, Well-Understood Unit Operations: Session 1.2. Anion Exchange Chromatography; and Session 1.3. Protein a Chromatography. PDA J. Pharm. Sci. Technol. 2015, 69 (1), 154–162.

    OpenUrlFREE Full Text
22. 22.↵
    1. Roush D.

    Viral Clearance Using Traditional, Well-Understood Unit Operations (Session I): Anion Exchange Chromatography (AEX). PDA J. Pharm. Sci. Technol. 2014, 68 (1), 23–29.

    OpenUrlFREE Full Text
23. 23.↵
    1. Banton D.,
    2. Vacante D.,
    3. Bulthuis B.,
    4. Goldstein J.,
    5. Wineburg M.,
    6. Schreffler J.

    The Use of Bayesian Hierarchical Logistic Regression in the Development of a Modular Viral Inactivation Claim. PDA J. Pharm. Sci. Technol. 2019, 73 (6), 552–561.

    OpenUrlAbstract/FREE Full Text
24. 24.↵
    1. Mattila J.,
    2. Clark M.,
    3. Liu S.,
    4. Pieracci J.,
    5. Gervais T. R.,
    6. Wilson E.,
    7. Galperina O.,
    8. Li X.,
    9. Roush D.,
    10. Zoeller K.,
    11. Brough H.,
    12. Simpson-Platre C.

    Retrospective Evaluation of Low-pH Viral Inactivation and Viral Filtration Data from a Multiple Company Collaboration. PDA J. Pharm. Sci. Technol. 2016, 70 (3), 293–299.

    OpenUrlAbstract/FREE Full Text
25. 25.↵
    1. Kreil T.,
    2. Roush D.

    Proceedings of the 2017 Viral Clearance Symposium, Session 2.1: DSP Unit Operation – Virus Filtration/Inactivation. PDA J. Pharm. Sci. Technol. 2018, 72 (5), 470–478.

    OpenUrlAbstract/FREE Full Text
26. 26.↵
    1. Bieberbach M.,
    2. Kosiol P.,
    3. Seay A.,
    4. Bennecke M.,
    5. Hansmann B.,
    6. Hepbildikler S.,
    7. Thom V.

    Investigation of Fouling Mechanisms of Virus Filters during the Filtration of Protein Solutions Using a High Throughput Filtration Screening Device. Biotechnol. Prog. 2019, 35 (4), 1–10.

    OpenUrl